INDOLENT NON-HODGKIN LYMPHOMA

This early-stage study is testing if adding a new drug called parsaclisib to a standard chemotherapy regimen (R-CHOP) is safe and more effective for patients with newly diagnosed, high-risk diffuse large B-cell lymphoma. The main goals are to find the safest dose of the new combi…

This study is testing whether adding the immunotherapy drug nivolumab to a standard chemotherapy regimen (called DA-REPOCH) works better for treating aggressive B-cell non-Hodgkin's lymphoma. The goal is to see if this combination helps patients live longer without their cancer g…

This was an early safety study for an experimental cancer drug called CB-5339. It was designed to find the safest dose and check for side effects in adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The study was withdrawn by the s…

This study is testing how well and how safely a combination of two immunotherapy drugs works for people with certain slow-growing lymphomas who have not yet received treatment. The drugs, glofitamab and obinutuzumab, are designed to help the body's own immune system find and atta…

This is an early-stage study to find the safest dose of two cancer drugs, copanlisib and nivolumab, when given together. It is for adults with aggressive blood cancers that have transformed from slower-growing types, like Richter's syndrome. The main goal is to see how well patie…

This study is testing how well two targeted drugs, obinutuzumab and ibrutinib, work together as the first treatment for people with certain slow-growing types of non-Hodgkin's lymphoma. The goal is to control the cancer by stopping cancer cells from growing and spreading, potenti…